What Analysts Are Recommending for Pfizer and Other Major Oncology Players in 2016
Among the 27 brokerage firms surveyed, 57.7% gave Pfizer’s stock a “buy” recommendation, while 42.3% gave a “hold” recommendation. None has given a “sell.”
Medivation has added its robust research pipeline with two promising investigational drugs, Talazoparib and Pidilizumab, to Pfizer’s oncology portfolio.
On June 6, Pfizer and Merck announced positive results from a Phase 2 study testing Avelumab as a therapy for previously treated Merkel cell carcinoma.
On September 28, 2016, Pfizer (PFE) announced the completion of its acquisition of Medivation for around $14 billion.
Pfizer (PFE) is confident that Xtandi will be able to penetrate a much larger market if the drug is approved for early-stage prostate cancer.
On January 26, 2006, the FDA approved Pfizer’s (PFE) Sutent as a therapy for patients suffering from GIST (gastrointestinal stromal tumors).
On January 27, 2012, the FDA approved Pfizer’s (PFE) Inlyta as a second-line therapy for patients suffering from advanced kidney cancer or RCC.
Pfizer (PFE) expects Ibrance to pose strong competition to upcoming CDK 4/6 inhibitor therapies from Novartis (NVS) and Eli Lilly (LLY).
On August 26, 2011, the FDA approved Pfizer’s (PFE) Xalkori for patients suffering from late-stage NSCLC and who express abnormal ALK gene.
On October 21, 2016, Pfizer was trading at a forward PE multiple of about 11.4x. Since January 1, 2016, it has traded at PE multiples of 11.2x–13.5x.
T-Mobile (TMUS) continues to see success with its “un-carrier” strategy.
Juniper issued upbeat guidance for the current quarter. EPS is expected in the range of $0.59–$ 0.64.
Apple posted EPS (earnings per share) of $1.67 on revenues of $46.9 billion in the last quarter.
On October 25, 2016, NRG Energy (NRG) was trading at a 5% and a 17% discount to its 50-day and 200-day moving averages, respectively.
According to Wall Street analyst estimates, NRG Energy (NRG) has an estimated upside of 54% in one year with a price target of $16.71.
As of October 25, 2016, NRG Energy (NRG) is trading at an EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple of 7.7x.
The largest independent power producer, NRG Energy (NRG), is scheduled to report its 3Q16 earnings on November 4, 2016.
37% of these analysts have recommended LYB as a “buy,” 58% have recommended it as a “hold,” and the remaining 5% have recommended it as a “sell.”
On October 24, 2016, LyondellBasell (LYB) was trading at a one-year forward PE multiple of 8.50x.
Analysts expect LyondellBasell (LYB) to post revenue of $7.4 billion in 3Q16, implying an 11.3% fall in projected revenue on a year-over-year basis.